文献速递中枢神经肿瘤放疗姑息放疗与转移瘤

接受免疫检查点抑制剂与立体定向放疗患者放射性坏死及颅内控制的相关因素

Factors associated with radiation necrosis and intracranial control in patients treated with immune checkpoint inhibitors and stereotactic radiotherapy.
PubMed 文献 · Radiother Oncol · 2023-09-26

研究纳入2013至2021年两家机构接受ICI联合SRS/SRT的非小细胞肺癌、肾细胞癌或黑色素瘤患者179例共549个转移灶。PD-L1≥50%可能与较高的2级及以上放射性坏死率相关,且发生放射性坏死后颅内控制可能更好;ICI联合SRS/SRT总体安全,同期给药可能带来局部控制获益。

要点

  • PD-L1≥50%与2级及以上放射性坏死率升高相关,多因素分析仍显著(p=0.03)。
  • 放疗前后±1个月内使用ICI者局部失败率低于未同期使用者(3% vs 8%,p=0.01)。
  • 发生2级及以上放射性坏死者颅内失败率低于未发生者(17% vs 54%,p=0.001)。

核心结论

  • PD-L1表达≥50%可能与较高的2级及以上放射性坏死率相关。
  • 发生放射性坏死后颅内控制可能更好。
  • ICI联合SRS/SRT总体安全,同期给药可能带来局部控制获益。

研究设计与样本

  • 研究为2013至2021年在两家机构接受ICI联合SRS/SRT治疗的非小细胞肺癌、肾细胞癌或黑色素瘤患者的分析。
  • 共纳入179例患者、549个转移灶,采用单因素和多因素分析局部失败及2级及以上放射性坏死的相关因素。

主要发现

  • 从SRS/SRT起中位随访14.7个月,中位肿瘤大小7 mm,其中46个肿瘤≥20 mm。
  • 每个转移灶的局部失败率和2级及以上放射性坏死率分别为5.8%(32/549)和6.9%(38/549)。
  • 放疗前后±1个月内使用ICI者与未同期使用者局部失败率分别为3%(8/264)和8%(24/285),p=0.01。
  • PD-L1≥50%者与PD-L1<50%者2级及以上放射性坏死率分别为17%(11/65)和3%(5/203),p<0.001;多因素分析PD-L1≥50%仍显著相关(p=0.03)。
  • 未发生与发生2级及以上放射性坏死者的颅内失败率分别为54%(80/147)和17%(4/23),p=0.001。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Emerging data suggest immune checkpoint inhibitors (ICI) and stereotactic radiosurgery (SRS) or radiotherapy (SRT) may work synergistically, potentially increasing both efficacy and toxicity. This manuscript characterizes factors associated with intracranial control and radiation necrosis in this group. MATERIALS AND METHODS: All patients had non-small cell lung cancer, renal cell carcinoma, or melanoma and were treated from 2013 to 2021 at two institutions with ICI and SRS/SRT. Univariate and multivariate analysis were used to analyze factors associated with local failure (LF) and grade 2+ (G2 + ) radiation necrosis. RESULTS: There were 179 patients with 549 metastases. The median follow up from SRS/SRT was 14.7 months and the median tumor size was 7 mm (46 tumors ≥ 20 mm). Rates of LF and G2 + radiation necrosis per metastasis were 5.8% (32/549) and 6.9% (38/549), respectively. LF rates for ICI +/- 1 month from time of radiation versus not were 3% (8/264) and 8% (24/285) (p = 0.01), respectively. G2 + radiation necrosis rates for PD-L1 ≥ 50% versus < 50% were 17% (11/65) and 3% (5/203) (p=<0.001), respectively. PD-L1 ≥ 50% remained significantly associated with G2 + radiation necrosis on multivariate analysis (p = 0.03). Rates of intracranial failure were 54% (80/147) and 17% (4/23) (p = 0.001) for those without and with G2 + radiation necrosis, respectively. CONCLUSIONS: PD-L1 expression (≥50%) may be associated with higher rates of G2 + radiation necrosis, and there may be improved intracranial control following the development of radiation necrosis. Administration of ICIs with SRS/SRT is overall safe, and there may be some local control benefit to delivering these concurrently.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Hall J, Lui K, Tan X, et al. Factors associated with radiation necrosis and intracranial control in patients treated with immune checkpoint inhibitors and stereotactic radiotherapy. Radiother Oncol. 2023. PMID: 37769968. doi:10.1016/j.radonc.2023.109920

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。